Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal JURNAL PENELITIAN KEBIDANAN & KESPRO Journal of Innovative and Creativity
Yahya, Nur Khalisha
Unknown Affiliation
Education Health Professions Languange, Linguistic, Communication & Media Mathematics Social Sciences Other

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Comparing Vaginal Misoprostol and Vaginal Dinoprostone on the Rate of Vaginal Delivery within 24 Hours Syaharani, Nabilla; Safitri, Yolanda; Saputri, Vivi Saharani; Salsabilla, Azira Isnaini; Yahya, Nur Khalisha; Yudistira, Dimas
Journal of Innovative and Creativity Vol. 6 No. 1 (2026)
Publisher : Fakultas Ilmu Pendidikan Universitas Pahlawan Tuanku Tambusai

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31004/joecy.v6i1.8900

Abstract

Background: Labor induction with misoprostol and vaginal dinoprostone remains controversial regarding its effectiveness in achieving vaginal delivery within 24 hours. Objective: To compare the efficacy and safety of misoprostol versus dinoprostone in term pregnancies. Methods: An Evidence-Based Clinical Review (EBCR) synthesized RCTs and meta-analyses using the PICO framework (Population: term pregnant women; Intervention: dinoprostone; Comparison: misoprostol; Outcome: vaginal delivery <24 hours). PubMed, Cochrane, and EBSCO were searched October 2025. The CEBM tool identified 3 studies (1 RCT, 2 meta-analyses). PRISMA 2020 guided the narrative synthesis. Population/Sample: Term singleton pregnancies; 3 included studies (Gaudineau et al., 2021; Lakho et al., 2024; Ramadan et al., 2024). Analysis: A critical appraisal assessed validity, effect size (RR, NNT), and heterogeneity (I²). Results: Misoprostol resulted in higher vaginal delivery rates (Gaudineau: RR 1.30, NNT 7; Ramadan: RR 1.15, 95% CI 1.08-1.22; Lakho: RR 1.08). Conclusion: Vaginal misoprostol was superior or equivalent, providing cost-effective advantages for limited facilities.
Efficacy and Safety of Labetalol Versus Methyldopa for Blood Pressure Control in Pregnant Women With Hypertension: Efficacy and Safety of Labetalol Versus Methyldopa for Blood Pressure Control in Pregnant Women With Hypertension Yahya, Nur Khalisha
JURNAL ILMIAH DHDT - KEBIDANAN Vol 8 No 2 (2026): JURNAL PENELITIAN KEBIDANAN & KESPRO
Publisher : Fakultas Kebidanan Institut Kesehatan Deli Husada

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Hypertension in pregnancy is a major contributor to maternal morbidity and mortality worldwide. Labetalol and methyldopa are widely recommended as first-line antihypertensive therapy; however, uncertainty remains regarding comparative effectiveness for optimal blood pressure (BP) control. This Evidence-based case Report evaluates the efficacy and safety of these agents to inform therapeutic selection. A comprehensive literature search was conducted in PubMed, Cochrane Library, Google Scholar, and EBSCO using the keywords (“Hypertension” AND “Pregnancy” AND “Labetalol” AND “Methyldopa” AND “Blood Pressure Control”). Eligible studies included randomized controlled trials (RCTs) and systematic reviews/meta-analyses comparing labetalol and methyldopa in pregnant women with hypertension were included. Data extraction prioritized maternal BP outcomes, reporting effect sizes as relative risk (RR), absolute risk reduction (ARR), and number needed to treat (NNT) with 95% confidence intervals (CI). Quality assessment was performed using the Centre for Evidence-Based Medicine (CEBM) appraisal tool. From 355 studies screened, two RCTs met eligibility. Labetalol provided a faster reduction in blood pressure (RR 1.35; 95% CI 1.01–1.80; NNT ≈ 6), while overall blood pressure control was comparable to methyldopa in longer-term outcomes (RR 0.99; 95% CI 0.92–1.06).Both labetalol and methyldopa demonstrate comparable clinical effectiveness as first-line therapy for hypertension in pregnancy. Drug selection should be individualized based on clinical urgency, tolerance, availability, and monitoring capacity. Early treatment and close follow-up remain the primary determinants of maternal–fetal outcomes
Co-Authors Safitri, Yolanda Salsabilla, Azira Isnaini Saputri, Vivi Saharani Syaharani, Nabilla Yudistira, Dimas